Literature DB >> 18855649

Cellular reservoirs of HIV-1 and their role in viral persistence.

Aikaterini Alexaki1, Yujie Liu, Brian Wigdahl.   

Abstract

A major obstacle in human immunodeficiency virus type 1 (HIV-1) eradication is the ability of the virus to remain latent in a subpopulation of the cells it infects. Latently infected cells can escape the viral immune response and persist for long periods of time, despite the presence of successful highly active antiretroviral therapy (HAART). Given the appropriate stimulus, latently infected cells can reactivate and start producing infectious virions. The susceptibility of these cell populations to HIV-1, their life span, their proliferative capacity, and their ability to periodically produce infectious virus subsequent to alterations in cellular physiology and/or immunologic controls are critical issues which determine the contribution of these cells to viral persistence. Memory CD4+ T cells due to the long life span, which may be several years, and their ability to reactivate upon encounter with their cognate antigen or other stimulation, are considered a critical reservoir for maintenance of latent HIV-1 proviral DNA. Cells of the monocyte-macrophage lineage, which originate in the bone marrow (BM), are of particular importance in HIV-1 persistence due to their ability to cross the blood-brain barrier (BBB) and spread HIV-1 infection in the immunoprivileged central nervous system (CNS). Hematopoietic progenitor cells (HPCs) are also a potential HIV-1 reservoir, as several studies have shown that CD34+ HPCs carrying proviral DNA can be found in vivo in a subpopulation of HIV-1-infected patients. The ability of HPCs to proliferate and potentially generate clonal populations of infected cells of the monocyte-macrophage lineage may be crucial in HIV-1 dissemination. The contribution of these and other cell populations in HIV-1 persistence, as well as the possible strategies to eliminate latently infected cells are critically examined in this review.

Entities:  

Mesh:

Year:  2008        PMID: 18855649      PMCID: PMC2683678          DOI: 10.2174/157016208785861195

Source DB:  PubMed          Journal:  Curr HIV Res        ISSN: 1570-162X            Impact factor:   1.581


  180 in total

1.  Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy.

Authors:  D Finzi; J Blankson; J D Siliciano; J B Margolick; K Chadwick; T Pierson; K Smith; J Lisziewicz; F Lori; C Flexner; T C Quinn; R E Chaisson; E Rosenberg; B Walker; S Gange; J Gallant; R F Siliciano
Journal:  Nat Med       Date:  1999-05       Impact factor: 53.440

Review 2.  Astrocytes: HIV cellular reservoirs and important participants in neuropathogenesis.

Authors:  R Brack-Werner
Journal:  AIDS       Date:  1999-01-14       Impact factor: 4.177

3.  Macrophage-inflammatory protein-1alpha receptor expression on normal and chronic myeloid leukemia CD34+ cells.

Authors:  S E Nicholls; G Lucas; G J Graham; N H Russell; R Mottram; A D Whetton; A M Buckle
Journal:  J Immunol       Date:  1999-05-15       Impact factor: 5.422

4.  Intrinsic human immunodeficiency virus type 1 resistance of hematopoietic stem cells despite coreceptor expression.

Authors:  H Shen; T Cheng; F I Preffer; D Dombkowski; M H Tomasson; D E Golan; O Yang; W Hofmann; J G Sodroski; A D Luster; D T Scadden
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

5.  Mycobacterium avium complex augments macrophage HIV-1 production and increases CCR5 expression.

Authors:  S M Wahl; T Greenwell-Wild; G Peng; H Hale-Donze; T M Doherty; D Mizel; J M Orenstein
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-13       Impact factor: 11.205

6.  Relative potency of protease inhibitors in monocytes/macrophages acutely and chronically infected with human immunodeficiency virus.

Authors:  C F Perno; F M Newcomb; D A Davis; S Aquaro; R W Humphrey; R Caliò; R Yarchoan
Journal:  J Infect Dis       Date:  1998-08       Impact factor: 5.226

7.  Peripheral blood-derived CD34+ progenitor cells: CXC chemokine receptor 4 and CC chemokine receptor 5 expression and infection by HIV.

Authors:  M E Ruiz; C Cicala; J Arthos; A Kinter; A T Catanzaro; J Adelsberger; K L Holmes; O J Cohen; A S Fauci
Journal:  J Immunol       Date:  1998-10-15       Impact factor: 5.422

Review 8.  Chemokine receptors in the human brain and their relationship to HIV infection.

Authors:  E Lavi; D L Kolson; A M Ulrich; L Fu; F González-Scarano
Journal:  J Neurovirol       Date:  1998-06       Impact factor: 2.643

9.  Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection.

Authors:  T W Chun; D Engel; M M Berrey; T Shea; L Corey; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-21       Impact factor: 11.205

10.  Induction of HIV-1 replication in latently infected CD4+ T cells using a combination of cytokines.

Authors:  T W Chun; D Engel; S B Mizell; L A Ehler; A S Fauci
Journal:  J Exp Med       Date:  1998-07-06       Impact factor: 14.307

View more
  168 in total

Review 1.  Genetic knockouts suggest a critical role for HIV co-receptors in models of HIV gp120-induced brain injury.

Authors:  Ricky Maung; Kathryn E Medders; Natalia E Sejbuk; Maya K Desai; Rossella Russo; Marcus Kaul
Journal:  J Neuroimmune Pharmacol       Date:  2011-11-29       Impact factor: 4.147

2.  Targeted axonal import (TAxI) peptide delivers functional proteins into spinal cord motor neurons after peripheral administration.

Authors:  Drew L Sellers; Jamie M Bergen; Russell N Johnson; Heidi Back; John M Ravits; Philip J Horner; Suzie H Pun
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-17       Impact factor: 11.205

Review 3.  Mitogen-activated protein kinase p38 in HIV infection and associated brain injury.

Authors:  Kathryn E Medders; Marcus Kaul
Journal:  J Neuroimmune Pharmacol       Date:  2011-02-01       Impact factor: 4.147

Review 4.  Towards nanomedicines for neuroAIDS.

Authors:  Vidya Sagar; Sudheesh Pilakka-Kanthikeel; Ravi Pottathil; Shailendra K Saxena; Madhavan Nair
Journal:  Rev Med Virol       Date:  2014-01-07       Impact factor: 6.989

Review 5.  Neuropharmacologic Approaches to Restore the Brain's Microenvironment.

Authors:  Weizhe Li; Hsin-I Tong; Santhi Gorantla; Larisa Y Poluektova; Howard E Gendelman; Yuanan Lu
Journal:  J Neuroimmune Pharmacol       Date:  2016-06-28       Impact factor: 4.147

6.  A comparison of methods for measuring rectal HIV levels suggests that HIV DNA resides in cells other than CD4+ T cells, including myeloid cells.

Authors:  Steven A Yukl; Elizabeth Sinclair; Ma Somsouk; Peter W Hunt; Lorrie Epling; Maudi Killian; Valerie Girling; Peilin Li; Diane V Havlir; Steven G Deeks; Joseph K Wong; Hiroyu Hatano
Journal:  AIDS       Date:  2014-01-28       Impact factor: 4.177

7.  Laser ablation for pharmaceutical nanoformulations: Multi-drug nanoencapsulation and theranostics for HIV.

Authors:  Ajay Singh; Hilliard L Kutscher; Julia C Bulmahn; Supriya D Mahajan; Guang S He; Paras N Prasad
Journal:  Nanomedicine       Date:  2020-02-13       Impact factor: 5.307

8.  Fatigue-related gene networks identified in CD(14)+ cells isolated from HIV-infected patients: part I: research findings.

Authors:  Joachim G Voss; Adrian Dobra; Caryn Morse; Joseph A Kovacs; Robert L Danner; Peter J Munson; Carolea Logan; Zoila Rangel; Joseph W Adelsberger; Mary McLaughlin; Larry D Adams; Raghavan Raju; Marinos C Dalakas
Journal:  Biol Res Nurs       Date:  2013-01-16       Impact factor: 2.522

9.  HIV-1 uses dynamic podosomes for entry into macrophages.

Authors:  Wei Li; Ji Liu; Yuanyuan Liu; Qin Li; Wen Yin; Kevin K Wanderi; Xiaowei Zhang; Zhiping Zhang; Xian-En Zhang; Zongqiang Cui
Journal:  J Virol       Date:  2021-02-24       Impact factor: 5.103

Review 10.  The meningeal lymphatic system: a route for HIV brain migration?

Authors:  Susanna L Lamers; Rebecca Rose; Lishomwa C Ndhlovu; David J Nolan; Marco Salemi; Ekaterina Maidji; Cheryl A Stoddart; Michael S McGrath
Journal:  J Neurovirol       Date:  2015-11-16       Impact factor: 2.643

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.